['melanoma']
['tlpldc', 'placebo']

        Inclusion Criteria:

          -  18 years or older

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0,1 (Appendix D)

          -  AJCC stage III or IV completely resectable melanoma identified before surgery

          -  Approximately 1 mg (1 cm3) of accessible and dispensable tumor that will not interfere
             with pathologic staging

          -  Clinically disease-free after surgery

          -  Completing SoC adjuvant therapy per NCCN guidelines to include chemotherapy, radiation
             therapy, and/or biologic therapy as clinically indicated. (Consent #2 should be signed
             as close to completion of SoC as possible but may overlap completion by up to one
             month.)

          -  Vaccinations initiated between 3 weeks and 3 months from completion of SoC
             multi-modality cancer care

          -  Adequate organ function as determined by the following laboratory values:

          -  ANC ≥ 1,000/μL

          -  Platelets ≥ 75,000/μL

          -  Hgb ≥ 9 g/dL

          -  Creatinine ≤ 1.5 x upper limit of normal (ULN) or Creatinine clearance ≥ 50%

          -  Total bilirubin ≤ 1.5 ULN

          -  ALT and AST ≤ 1.5 ULN

          -  For women of child-bearing potential, agreement to use adequate birth control
             (abstinence, hysterectomy, bilateral oophorectomy, bilateral tubal ligation, oral
             contraception, IUD, or use of condoms or diaphragms)

          -  Signed informed consent

        Exclusion Criteria:

          -  Evidence of residual disease after surgery and SoC adjuvant therapies

          -  Insufficient tumor available to produce vaccine

          -  ECOG >2 performance status (Appendix D)

          -  Immune deficiency disease or known history of HIV, HBV, HCV

          -  Receiving immunosuppressive therapy including chronic steroids, methotrexate, or other
             known immunosuppressive agents

          -  Pregnancy (assessed by urine HCG)

          -  Breast feeding

          -  Active pulmonary disease requiring medication to include multiple inhalers (>2
             inhalers and one containing steroids)

          -  Involved in other experimental protocols (except with permission of the other study
             PI)
      